Publications and communications of Ferman Agirman

Gullo, C.* , Laverdeur, E.* , Dancre, M., Peiffer, R., Boumahd, Y., Agirman, F., Maloujahmoum, N., Désiront, L., Thiry, M., Rademaker, G., Bellahcene, A., & Peulen, O. (28 November 2025). Focal adhesion assembly and cell migration require myoferlin in PDAC cell lines. Scientific Reports, 15 (1). doi:10.1038/s41598-025-27134-2

Lardinois, F., Mohring, V., Maloujahmoum, N., Agirman, F., Chariot, A., Rapino, F., Peulen, O., & Bellahcene, A. (24 October 2025). Methylglyoxal as a metabolic vulnerability of cancer stem cells in 5-FU resistant colorectal cancer [Poster presentation]. BACR, Belgium.

Peiffer, R., Laverdeur, E., Gaigneaux, A., Boumahd, Y., Gullo, C., Rademaker, G., Crake, R., Lavergne, A., Maloujahmoum, N., Agirman, F., Herfs, M., Masamune, A., Letellier, E., Bellahcene, A., & Peulen, O. (2025). Targeting myoferlin in ER/Golgi vesicle trafficking reprograms pancreatic cancer-associated fibroblasts. EMBO Journal. doi:10.1038/s44318-025-00570-6

Lardinois, F., Mohring, V., Maloujahmoum, N., Agirman, F., Chariot, A., Rapino, F., Peulen, O., & Bellahcene, A. (29 September 2025). METHYLGLYOXAL: A METABOLIC VULNERABILITY IN RESISTANT COLORECTAL CANCER STEM CELLS [Poster presentation]. Stem Cells & Cancer Conference, Malta.

Lardinois, F., Mohring, V., Maloujahmoum, N., Agirman, F., Peulen, O., & Bellahcene, A. (12 September 2025). Methylglyoxal as a metabolic liability in cancer stem cells from 5-FU–resistant colorectal cancer [Paper presentation]. GIGA Day, Belgium.

Lardinois, F., Mohring, V., Maloujahmoum, N., Agirman, F., Chariot, A., Rapino, F., Peulen, O., & Bellahcene, A. (03 July 2025). Targeting methylglyoxal reveals a metabolic weakness in 5-FU–resistant colorectal cancer stem cells [Poster presentation]. 12th ISCaM meeting, Bruxelles, Belgium.

Mohring, V., Hubert, P., Ancion, M., Nokin, M.-J., Roncarati, P., Agirman, F., Maloujahmoum, N., Lardinois, F., Wissocq, T., Herfs, M., Peulen, O., Janji, B., & Bellahcene, A. (July 2025). Targeting methylglyoxal stress to overcome immunosuppression and metastasis in triple-negative breast cancer [Poster presentation]. ISCAM 2025 symposium.

Lardinois, F., Mohring, V., Crake, R., Maloujahmoum, N., Agirman, F., Rapino, F., Peulen, O., & Bellahcene, A. (23 May 2025). Targeting glycation stress in chemoresistant colon cancer: implications for cancer stem cells [Paper presentation]. EDT-cancer, Belgium.

Mohring, V., Hubert, P., Ancion, M., Nokin, M.-J., Roncarati, P., Agirman, F., Maloujahmoum, N., Lardinois, F., Wissocq, T., Herfs, M., Peulen, O., & Janji, B. (23 May 2025). HOW GLYCATION STRESS AFFECTS THE TUMOR IMMUNE MICROENVIRONMENT IN BREAST CANCER ? [Paper presentation]. Annual meeting of the doctoral school in cancerology (EDT-cancer).

Lardinois, F., Mohring, V., Martin Morales, L., Maloujahmoum, N., Agirman, F., Chariot, A., Rapino, F., Peulen, O., & Bellahcene, A. (25 October 2024). Targeting glycation stress in chemoresistant colon cancer: Impact on cancer stem cells [Poster presentation]. Metabolism Contact Group Meeting, Bruxelles, Belgium.

Mohring, V., Hubert, P., Ancion, M., Nokin, M.-J., RONCARATI, P., Agirman, F., Maloujahmoum, N., Lardinois, F., Wissocq, T., Herfs, M., Peulen, O., Janji, B., & Bellahcene, A. (25 October 2024). Enhancing immune response and preventing breast cancer spread by lowering methylglyoxal stress [Poster presentation]. Metabolism Contact Group Meeting.

Lardinois, F., Mohring, V., Martin Morales, L., Maloujahmoum, N., Agirman, F., Chariot, A., Rapino, F., Peulen, O., & Bellahcene, A. (18 October 2024). Targeting glycation stress in chemoresistant colon cancer: Effects on cancer stem cells [Poster presentation]. BACR, Bruxelles, Belgium.

Mohring, V., Hubert, P., Ancion, M., Nokin, M.-J., RONCARATI, P., Agirman, F., Maloujahmoum, N., Lardinois, F., Wissocq, T., Herfs, M., Peulen, O., Janji, B., & Bellahcene, A. (17 September 2024). Investigating the effects of methylglyoxal stress on immune response to tumors [Paper presentation]. IMARS-15 Congress, Maastricht, Netherlands.

Lardinois, F., Mohring, V., Crake, R., Maloujahmoum, N., Agirman, F., Chariot, A., Rapino, F., Peulen, O., & Bellahcene, A. (September 2024). Blocking glycation stress in chemoresistant colon cancer: Effects on cancer stem cells [Poster presentation]. IMARS, Maastricht, Netherlands.

Boumahd, Y., Colin, G., Peiffer, R., Gullo, C., Agirman, F., Maloujahmoum, N., Coucke, P., Bellahcene, A., & Peulen, O. (04 July 2024). Modulation of radiosensitivity by myoferlin pharmacological targeting in human pancreatic cancer cell lines [Poster presentation]. IsCam 2024, Bruxelles, Belgium.

Mohring, V., Hubert, P., Ancion, M., Nokin, M.-J., RONCARATI, P., Agirman, F., Maloujahmoum, N., Lardinois, F., Wissocq, T., Herfs, M., Peulen, O., Janji, B., & Bellahcene, A. (04 July 2024). EXAMINING THE INFLUENCE OF METHYLGLYOXAL STRESS ON THE IMMUNE RESPONSE TO TUMORS [Paper presentation]. 11th ISCAM Meeting.

Anania, S., Farnir, M., Peiffer, R., Boumahd, Y., Thiry, M., Agirman, F., Maloujahmoum, N., Bellahcene, A., & Peulen, O. (17 February 2024). Identification of myoferlin as a mitochondria-associated membranes component required for calcium signaling in PDAC cell lines. Cell Communication and Signaling, 22 (1), 133. doi:10.1186/s12964-024-01514-z

Mohring, V., Hubert, P., Ancion, M., Nokin, M.-J., Roncarati, P., Agirman, F., Maloujahmoum, N., Lardinois, F., Wissocq, T., Herfs, M., Peulen, O., Janji, B., & Bellahcene, A. (06 February 2024). Exploring the impact of methylglyoxal stress on tumor immunity [Poster presentation]. Séminaire Télévie 2024.

Mohring, V., Hubert, P., Ancion, M., Nokin, M.-J., RONCARATI, P., Agirman, F., Maloujahmoum, N., Lardinois, F., Wissocq, T., Herfs, M., Peulen, O., Janji, B., & Bellahcene, A. (2024). Scrutinizing the impact of methylglyoxal stress on tumor immune response [Poster presentation]. VIB conference : “**Recent insights into Immuno-Oncology (2nd edition)**”, Anvers, Belgium.

Mohring, V., Hubert, P., Ancion, M., Nokin, M.-J., RONCARATI, P., Agirman, F., Maloujahmoum, N., Lardinois, F., Wissocq, T., Herfs, M., Peulen, O., Janji, B., & Bellahcene, A. (2024). Reducing Methylglyoxal Stress to Amplify Immune Response and Inhibit Breast Cancer Spread [Poster presentation]. BACR annual meeting.

Mohring, V., Hubert, P., Ancion, M., Nokin, M.-J., RONCARATI, P., Agirman, F., Maloujahmoum, N., Lardinois, F., Wissocq, T., Herfs, M., Peulen, O., Janji, B., & Bellahcene, A. (2024). Impact of Methylglyoxal stress on the immune system within the breast cancer environment [Poster presentation]. Giga Day.

Mohring, V., Hubert, P., Ancion, M., Nokin, M.-J., Roncarati, P., Agirman, F., Maloujahmoum, N., Lardinois, F., Wissocq, T., Herfs, M., Peulen, O., Janji, B., & Bellahcene, A. (27 October 2023). Methylglyoxal stress : a novel role in tumor immunity ? [Poster presentation]. Annual Meeting of the Belgian Association for Cancer Research (BACR).

Boumahd, Y., Colin, G., Peiffer, R., Gullo, C., Agirman, F., Maloujahmoum, N., Coucke, P., Bellahcene, A., & Peulen, O. (04 September 2023). Modulation of radiosensitivity by myoferlin pharmacological targeting in human pancreatic cancer cell lines [Poster presentation]. GIGA day 2023, Liège, Belgium.

Crake, R., Gasmi, I., Dehaye, J., Lardinois, F., Peiffer, R., Maloujahmoum, N., Agirman, F., KOOPMANSCH, B., D’Haene, N., Azurmendi Senar, O., Arsenijevic, T., Lambert, F., Peulen, O., Van Laethem, J.-L., & Bellahcene, A. (17 May 2023). Resistance to Gemcitabine in Pancreatic Cancer Is Connected to Methylglyoxal Stress and Heat Shock Response. Cells, 12 (10), 1414. doi:10.3390/cells12101414

Peiffer, R., Boumahd, Y., Gullo, C., Agirman, F., Maloujahmoum, N., Masamune, A., Letellier Elisabeth, Bellahcene, A., & Peulen, O. (03 May 2023). Myoferlin, a new drug target in pancreatic CAFs, promotes desmoplasia and tumor aggressiveness [Poster presentation]. Gordon Research Conference - Pancreatic Diseases, Lucca, Italy.

Rademaker, G., Costanza, B., Bellier, J., Herfs, M., Peiffer, R., Agirman, F., Maloujahmoum, N., Habraken, Y., Delvenne, P., Bellahcene, A., Castronovo, V., & Peulen, O. (02 March 2023). Correction: Human colon cancer cells highly express myoferlin to maintain a fit mitochondrial network and escape p53-driven apoptosis. Oncogenesis, 12 (1), 11. doi:10.1038/s41389-023-00455-5

Mohring, V., Hubert, P., Ancion, M., Nokin, M.-J., Roncarati, P., Agirman, F., Maloujahmoum, N., Lardinois, F., Wissocq, T., Herfs, M., Peulen, O., & Janji, B. (2023). Enhancement of anti-tumor immunity through interference with glycation stress in breast cancer [Poster presentation]. GIGA day.

Boumahd, Y., Rademaker, G., Peiffer, R., Anania, S., Gullo, C., Agirman, F., Maloujahmoum, N., Bellahcene, A., & Peulen, O. (30 September 2022). Myoferlin targeting triggers mitophagy and primes ferroptosis in pancreatic cancer cells. Investigation of STAT3 involvement [Poster presentation]. BACR 2022, Gand, Belgium.

Mouziane, L., Crake, R., Maloujahmoum, N., Agirman, F., Roncarati, P., Herfs, M., & Bellahcene, A. (30 September 2022). Characterisation of methylglyoxal stress in human colorectal cancer and liver metastases using immunohistochemistry [Poster presentation]. BACR, Gent, Belgium.

Peiffer, R., Boumahd, Y., Anania, S., Gullo, C., Agirman, F., Maloujahmoum, N., Masamune Atsushi, Letellier Elisabeth, Bellahcene, A., & Peulen, O. (30 September 2022). The role of myoferlin in PDAC fibroblasts and desmoplasia [Poster presentation]. BACR - annual meeting 2022, Ghent, Belgium.

Peiffer, R., Boumahd, Y., Anania, S., Gullo, C., Agirman, F., Maloujahmoum, N., Asamune, A., Letellier, E., Bellahcene, A., & Peulen, O. (06 September 2022). The role of myoferlin in pancreatic cancer fibroblasts and desmoplasia [Poster presentation]. GIGA Day 2022, Liège, Belgium.

Rademaker, G.* , Boumahd, Y.* , Peiffer, R., Anania, S., Wissocq, T., Liégeois, M., Luis, G., Sounni, N. E., Agirman, F., Maloujahmoum, N., De Tullio, P., Thiry, M., Bellahcene, A., Castronovo, V., & Peulen, O. (July 2022). Myoferlin targeting triggers mitophagy and primes ferroptosis in pancreatic cancer cells. Redox Biology, 53, 102324. doi:10.1016/j.redox.2022.102324

Boumahd, Y., Rademaker, G., Peiffer, R., Anania, S., Agirman, F., Maloujahmoum, N., Bellahcene, A., & Peulen, O. (22 June 2022). Myoferlin targeting triggers mitophagy and primes ferroptosis in pancreatic cancer cells [Poster presentation]. EACR 2022.

Peiffer, R., Anania, S., Boumahd, Y., Agirman, F., Maloujahmoum, N., Masamune, A., Letellier, E., Bellahcene, A., & Peulen, O. (June 2022). The oncoprotein myoferlin as potential new participant in myCAF activity in pancreatic cancer [Poster presentation]. EACR 2022, Sevilla, Spain.

Boumahd, Y., Rademaker, G., Peiffer, R., Anania, S., Gullo, C., Agirman, F., Maloujahmoum, N., Bellahcene, A., & Peulen, O. (2022). Myoferlin targeting triggers mitophagy and primes ferroptosis in pancreatic cancer cells. Investigation on the involvement of STAT3 [Paper presentation]. GIGA Day 2022, Liège, Belgium.

Gullo, C., Boumahd, Y., Peiffer, R., Anania, S., Agirman, F., Maloujahmoum, N., Thiry, M., Bellahcene, A., & Peulen, O. (2022). Myoferlin controls beta actin cytoskeleton integrity in pancreas cancer [Paper presentation]. GIGA Day 2022, Liège, Belgium.

Rademaker, G., Costanza, B., Pyr Dit Ruys, S., Peiffer, R., Agirman, F., Maloujahmoum, N., Vertommen, D., Turtoi, A., Bellahcene, A., Castronovo, V.* , & Peulen, O.*. (2022). Paladin, overexpressed in colon cancer, is required for actin polymerisation and liver metastasis dissemination. Oncogenesis, 11, 42. doi:10.1038/s41389-022-00416-4

Boumahd, Y., Rademaker, G., Peiffer, R., Anania, S., Maloujahmoum, N., Agirman, F., Bellahcene, A., & Peulen, O. (14 December 2021). Myoferlin targeting primes ferroptosis in pancreatic cancer cells [Poster presentation]. GIGA cancer day.

Peiffer, R., Anania, S., Boumahd, Y., Agirman, F., Maloujahmoum, N., Bossicard, Y., Masamune, A., Letellier, E., Bellahcene, A., & Peulen, O. (December 2021). Deciphering the role of myoferlin in pancreatic stellate cells, key players in the pancreatic tumor microenvironment [Poster presentation]. GIGA-Cancer day 2021, Liège, Belgium.

Crake, R., Agirman, F., Arsenijevic, T., Maloujahmoum, N., Peulen, O., Van Laethem, J.-L., & Bellahcene, A. (14 October 2021). Improving pancreatic cancer response to gemcitabine by overcoming methylglyoxal driven suppression of AMPK [Poster presentation]. GIGA-Cancer Day, Liege, Belgium.

Anania, S., Boumahd, Y., Peiffer, R., Thiry, M., Hego, A., Maloujahmoum, N., Agirman, F., Bellahcene, A., & Peulen, O. (June 2021). Myoferlin, a promising therapeutic target in PDAC, is located in mitochondria-associated membranes [Poster presentation]. 27TH CONGRESS OF THE EUROPEAN ASSOCIATION FOR CANCER RESEARCH.

Peiffer, R., Anania, S., Boumahd, Y., Agirman, F., Maloujahmoum, N., Bossicard, Y., Masamune, A., Letellier, E., Bellahcene, A., & Peulen, O. (June 2021). New insights on the role of myoferlin in pancreatic stellate cells, the key orchestrators of pancreatic tumor microenvironment [Poster presentation]. EACR 2021.

Anania, S., Peiffer, R., Rademaker, G., Hego, A., Thiry, M., Deldicque, L., Francaux, M., Maloujahmoum, N., Agirman, F., Bellahcene, A., Castronovo, V., & Peulen, O. (21 June 2020). Myoferlin is a yet unknown interactor of the mitochondrial dynamics’ machinery in pancreas cancer cells. Cancers, 12 (6), 1643. doi:10.3390/cancers12061643

Bellier, J., Nokin, M.-J., Caprasse, M., Tiamiou, A., Blomme, A., Scheijen, J. L., KOOPMANSCH, B., MacKay, G. M., Chiavarina, B., Costanza, B., Rademaker, G., Durieux, F., Agirman, F., Maloujahmoum, N., Cusumano, P. G., LOVINFOSSE, P., Leung, H. Y., LAMBERT, F., Bours, V., ... Bellahcene, A. (04 February 2020). Methylglyoxal Scavengers Resensitize KRAS-Mutated Colorectal Tumors to Cetuximab. Cell Reports, 30 (5), 1400-1416.e6. doi:10.1016/j.celrep.2020.01.012

Anania, S., Rademaker, G., Peiffer, R., Hego, A., Deldicque, L., Maloujahmoum, N., Agirman, F., Bellahcene, A., Castronovo, V., & Peulen, O. (February 2020). Role of myoferlin in mitochondrial dynamics and metabolic fitness of pancreas cancer [Poster presentation]. BACR Annual Meeting 2020 - Cancer metastases: from bedside to bench, Brussels, Belgium.

Rademaker, G., Costanza, B., Anania, S., Agirman, F., Maloujahmoum, N., Bellahcene, A., Castronovo, V., & Peulen, O. (December 2019). Myoferlin Contributes to the Metastatic Phenotype of Pancreatic cancer cells by enhancing the migratory capacity through the control of oxidative phosphorylation [Poster presentation]. Cirm Annual meeting.

Rademaker, G., Costanza, B., Bellier, J., Herfs, M., Agirman, F., Maloujahmoum, N., Bellahcene, A., Castronovo, V., & Peulen, O. (26 November 2019). Myoferlin depletion induces DNA damage response and p53- dependent cell cycle arrest and apoptosis in colon cancer [Poster presentation]. Metabolism in Cancer and Stromal Cells (2nd edition), Leuven, Belgium.

Rademaker, G., Costanza, B., Anania, S., Agirman, F., Maloujahmoum, N., Bellahcene, A., Castronovo, V., & Peulen, O. (November 2019). Myoferlin Contributes to the Metastatic Phenotype of Pancreatic cancer cells by enhancing the migratory capacity through the control of oxidative phosphorylation [Poster presentation]. Bioforum Uliège.

Rademaker, G., Costanza, B., Anania, S., Agirman, F., Maloujahmoum, N., Bellahcene, A., Castronovo, V., & Peulen, O. (23 October 2019). Myoferlin Contributes to the Metastatic Phenotype of Pancreatic Cancer Cells by Enhancing Their Migratory Capacity Through the Control of Oxidative Phosphorylation [Poster presentation]. Pancreatic Cancer Symposium, Toulouse, France.

Rademaker, G., Costanza, B., Anania, S., Agirman, F., Maloujahmoum, N., Bellahcene, A., Castronovo, V., & Peulen, O. (13 June 2019). Myoferlin Contributes to the Metastatic Phenotype of Pancreatic Cancer Cells by Enhancing Their Migratory Capacity Through the Control of Oxidative Phosphorylation [Poster presentation]. Belgian Society for Cell and Developmental Biology - Spring Meeting, Liège, Belgium.

Rademaker, G., Costanza, B., Anania, S., Agirman, F., Maloujahmoum, N., Di Valentin, E., Goval, J.-J., Bellahcene, A., Castronovo, V., & Peulen, O. (June 2019). Myoferlin contributes to the metastatic phenotype of pancreatic cancer cells by enhancing their migratory capacity through the control of oxidative phosphorylation. Cancers, 11 (6). doi:10.3390/cancers11060853

Rademaker, G., Costanza, B., Bellier, J., Herfs, M., Agirman, F., Maloujahmoum, N., Bellahcene, A., Castronovo, V., & Peulen, O. (2019). Human colon cancer overexpress myoferlin to maintain a fit mitochondrial network and escape p53 dependent apoptosis [Poster presentation]. Belgian Association for Cancer Research Congress, Anvers, Belgium.

Rademaker, G., Costanza, B., Bellier, J., Herfs, M., Peiffer, R., Agirman, F., Maloujahmoum, N., Habraken, Y., Delvenne, P., Bellahcene, A., Castronovo, V.* , & Peulen, O.*. (2019). Human colon cancer cells highly express myoferlin to maintain a fit mitochondrial network and escape p53-driven apoptosis. Oncogenesis. doi:10.1038/s41389-019-0130-6

Rademaker, G., Costanza, B., Bellier, J., Herfs, M., Agirman, F., Maloujahmoum, N., Bellahcene, A., Castronovo, V., & Peulen, O. (2018). Myoferlin depletion induces DNA damage response and p53 dependent cell cycle arrest and apoptosis in colon cancer [Poster presentation]. Third Symposium of UBRC, Bruxelles, Belgium.